Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Vox Sanguinis|March 9, 2026
Pre-exposure prophylaxis use in blood donors in EnglandJaid Debrah, Claire Reynolds, Victoria Maddox, et al.Bioanalysis|November 20, 2018
Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milkJoshua Gini, Sujan Dilly Penchala, Alieu Amara, et al.The Journal of Antimicrobial Chemotherapy|October 19, 2014
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MSAdeniyi Olagunju, Oluseye O Bolaji, Alieu Amara, et al.AIDS Research and Treatment|March 29, 2012
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan AdultsMohammed Lamorde, Pauline Byakika-Kibwika, William S Tamale, et al.Antimicrobial Agents and Chemotherapy|November 14, 2018
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-AmodiaquineStephen I Walimbwa, Mohammed Lamorde, Catriona Waitt, et al.Antimicrobial Agents and Chemotherapy|December 21, 2011
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 studyLaura J Else, Akil Jackson, Rebekah Puls, et al.The Journal of Antimicrobial Chemotherapy|May 16, 2021
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)Carolina Herrera, Julianne Lwanga, Ming Lee, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.Journal of Medical Internet Research|August 23, 2017
Development and Deployment of the OpenMRS-Ebola Electronic Health Record System for an Ebola Treatment Center in Sierra LeoneShefali Oza, Darius Jazayeri, Jonathan M Teich, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionRichard FitzGerald, Laura Dickinson, Laura Else, et al.Pageof 4